Ionis Pharmaceuticals
Trade Ionis Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
IONS Key Statistics
Stock Snapshot
Ionis Pharmaceuticals(IONS) stock is priced at $44.65, giving the company a market capitalization of 7.39B. It carries a P/E multiple of -12.62.
As of 2026-09-25, Ionis Pharmaceuticals(IONS) stock has fluctuated between $43.64 and $45.28. The current price stands at $44.65, placing the stock +2.3% above today's low and -1.4% off the high.
Ionis Pharmaceuticals(IONS) shares are trading with a volume of 6.14M, against a daily average of 5.31M.
During the past year, Ionis Pharmaceuticals(IONS) stock moved between $43.01 at its lowest and $86.74 at its peak.
During the past year, Ionis Pharmaceuticals(IONS) stock moved between $43.01 at its lowest and $86.74 at its peak.
IONS News
Ionis Pharmaceuticals (NasdaqGS:IONS) reported two positive Phase 3 trial readouts on 24 September 2026 for late stage RNA-targeted drugs. Sefaxersen, partnere...
Ionis Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from Needham maintained a Buy rating...
Ionis Pharmaceuticals IONS announced positive results from two partnered programs, both of which are in phase III development. IONS Secures Phase III Win in AL...
Analyst ratings
81%
of 27 ratingsMore IONS News
Ionis Pharmaceuticals (IONS) and Roche (RHHBY) announced on Wednesday that their RNA-targeting therapy sefaxersen succeeded in a late-stage trial for patients w...
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoin...
The latest announcement is out from Ionis Pharmaceuticals ( (IONS) ). On September 23, 2026, Ionis Pharmaceuticals and partner Roche reported that their Phase...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Ionis Pharmaceuticals and keeping the price target at $100.00. Mitchell Kapoor has given...
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Otsuka on Tuesday shared positive topline results from their Phase 3 FUSION trial. The trial evaluated ulefnersen,...
Cathie Wood is doubling down on biotech, but investors looking beyond her ARK Genomic Revolution ETF (BATS:ARKG) have several other ways to gain exposure to the...
Ionis Pharmaceuticals (IONS) and Otsuka (OTSKY) Pharmaceutical Development & Commercialization announced topline results from the Phase 3 FUSION trial evaluatin...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.